GlassScriptPhysician profile
Gary Ross Farris
NPI 1720498074
$4,484.09
in general payments reported to CMS, 2019-2025
29 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $65.01 · 2021: $440 · 2022: $667 · 2023: $1,070 · 2024: $1,233 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,312.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,037.43 | 2021-2025 | Leqvio |
| Merck Sharp & Dohme LLC | $433.26 | 2021-2024 | Verquvo |
| Amgen INC. | $404.74 | 2020-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $395.32 | 2021-2024 | Xarelto |
| Pfizer INC. | $355.07 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $232.12 | 2023-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $181.76 | 2022-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $176.33 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.00 | 2023-2025 | Jardiance |
| Abbott Laboratories | $159.29 | 2021-2025 | Accent |
| Astrazeneca Pharmaceuticals LP | $128.36 | 2021-2025 | Wainua, Farxiga |
| Boston Scientific Corporation | $127.54 | 2022-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Emd Serono, INC. | $113.01 | 2023 | Mavenclad |
| Novo Nordisk INC | $99.17 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Lexicon Pharmaceuticals, INC. | $57.85 | 2023 | Inpefa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $55.80 | 2025 | |
| Esperion Therapeutics, INC. | $54.28 | 2022-2025 | Nexletol |
| Irhythm Technologies, INC. | $49.78 | 2021-2022 | |
| Scpharmaceuticals INC. | $38.76 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $37.55 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $26.68 | 2023 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $21.54 | 2023 | Opsumit |
| Lilly USA, LLC | $21.14 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.19 | 2025 | |
| Astellas Pharma US INC | $19.16 | 2021 | |
| Bridgebio Pharma, INC. | $16.40 | 2025 | Attruby |
| Ge Healthcare | $16.09 | 2022 | |
| Medtronic, INC. | $15.74 | 2024 | Telescope |
| Alnylam Pharmaceuticals INC. | $15.73 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Farris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.